1. Blog

Lipoprotein(a): inherited risk and why units matter

Lipoprotein(a), or Lp(a), is a cholesterol-carrying particle whose level is mostly set by your genes. European guidelines advise measuring it at least once in adult life. Results come in two units, mg/dL and nmol/L, and they cannot be converted…

7 min de lectura

En este artículo
  1. What Lp(a) is
  2. Why it is called an inherited risk
  3. Once in a lifetime
  4. The units problem
  5. What to do with a result
  6. Testing at Santé Labs
  7. FAQ

Lipoprotein(a), or Lp(a), is a cholesterol-carrying particle whose level is mostly set by your genes. European guidelines advise measuring it at least once in adult life. Results come in two units, mg/dL and nmol/L, and they cannot be converted reliably. Always read your number against the unit and cut-offs on your own report.

Key takeaways

  • More than 90% of the variation in Lp(a) levels is explained by genetic variation at a single gene, LPA [1].
  • The European Atherosclerosis Society advises measuring Lp(a) at least once in adults, ideally with the first lipid profile [1].
  • Mass units (mg/dL) and molar units (nmol/L) measure different things. The EAS panel advises against using a fixed conversion factor [1].
  • Lifestyle changes have little effect on Lp(a) itself, so the result is usually read alongside your other risk factors [1].
  • Lp(a) is not part of any profile you can book at Santé Labs today.

What Lp(a) is

Lp(a) looks a lot like an LDL particle, the main carrier of "bad" cholesterol. The difference is an extra protein attached to it, called apolipoprotein(a), or apo(a).

Apo(a) comes in many sizes. The size depends on how many times one section of the gene, called the kringle IV type 2 repeat, is copied. This repeat explains around 30% to 70% of the variation in Lp(a) concentration between people [1]. People with fewer repeats tend to make smaller apo(a) and tend to have higher Lp(a) levels [1].

The Spanish Society of Arteriosclerosis (SEA) cites EAS data suggesting that around 20% to 25% of people have levels above 50 mg/dL [4].

Why it is called an inherited risk

Most blood lipids move with diet, weight, exercise and medication. Lp(a) mostly does not.

The EAS consensus states that Lp(a) levels are "predominantly (>90%) determined by genetic variability at the LPA locus" [1]. It also notes that lifestyle interventions have minimal impact. A low carbohydrate, high fat diet may lower levels by 10% to 15% [1].

Because the level is largely inherited, relatives can share it. The EAS suggests it seems reasonable to measure Lp(a) if a parent or sibling has markedly elevated levels [1]. The SEA recommends testing first-degree relatives of people with elevated Lp(a) or a family history of early cardiovascular disease [4]. If someone in your family has a high result, discuss whether testing makes sense for you with your doctor.

High Lp(a) is linked to atherosclerotic cardiovascular disease. Since 2013, the LPA gene has also been established as a major contributor to aortic valve stenosis risk [1].

Once in a lifetime: what the guidelines say

European guidelines

The 2019 ESC/EAS dyslipidaemia guidelines advised that Lp(a) measurement should be considered at least once in each adult's lifetime. The aim was to identify people with very high inherited levels, above 180 mg/dL (above 430 nmol/L), whose lifetime risk may be similar to that of heterozygous familial hypercholesterolaemia [2].

The 2022 EAS consensus statement went further. It says Lp(a) should be measured at least once in adults, preferably in the first lipid profile. It adds that repeated measurement is not required because it does not improve risk prediction [1]. Exceptions include kidney disease, liver disease and acute infection, which can change levels [1].

The 2025 ESC/EAS focused update suggests that raised Lp(a), above 50 mg/dL (above 105 nmol/L), can be treated as a factor that adds to cardiovascular risk when doctors estimate it [3]. How exactly it applies to you is a question for your doctor.

Spanish guidance

The SEA consensus suggests measuring Lp(a) in the whole population at least once in a lifetime, ideally at the earliest opportunity and with another lipid profile [4]. It recommends repeat testing only in specific cases, such as advanced kidney failure, nephrotic syndrome, or borderline results first measured in childhood, pregnancy or during an acute illness [4].

The units problem: mg/dL vs nmol/L

Two units, two different measurements

A result in mg/dL reports the mass of the whole Lp(a) particle. A result in nmol/L reports the number of particles.

Because apo(a) comes in many sizes, particles have different weights. Two people with the same number of particles can have different mass results. This is why the SEA describes mass-to-molar conversion as metrologically flawed [4].

Why there is no safe conversion factor

The EAS panel "does not recommend using a standard factor to convert between mg/dL and nmol/L". It calls a factor of 2 to 2.5 only a best guess [1]. The SEA agrees that conversion gives only a rough idea, mainly useful to see whether a value is very high or very low [4].

You can see the problem inside the guidelines themselves. The same 50 mg/dL cut-off is paired with 125 nmol/L in the 2022 EAS statement and with 105 nmol/L in the 2025 ESC/EAS update [1][3].

Thresholds at a glance

Category mg/dL nmol/L Source Caveat
Risk unlikely ("rule out") below 30 below 75 EAS 2022 [1] Not a lab reference range
Grey zone 30 to 50 75 to 125 EAS 2022 [1] Read with other risk factors
Higher risk ("rule in") above 50 above 125 EAS 2022 [1] Same mg/dL cut-off paired with a different nmol/L value in 2025
Risk-enhancing factor above 50 above 105 ESC/EAS 2025 [3] Used to refine overall risk, not as a diagnosis
Very high inherited level above 180 above 430 ESC/EAS 2019 [2], SEA [4] Risk may resemble familial hypercholesterolaemia

These are guideline decision points, not universal reference ranges. Laboratories set their own reference intervals, and methods, units and cut-offs can differ by lab. Sex and age can also matter for how a result is read. Always use the range printed on your own report.

What to do with a result

A single Lp(a) number does not diagnose anything. Guidelines use it to refine overall cardiovascular risk alongside LDL cholesterol, blood pressure, smoking, diabetes and family history [3].

Practical points:

  • Keep a copy of your report and note the unit. A future test in a different unit cannot be compared directly.
  • If your result is above the threshold on your report, discuss it and your other risk factors with your doctor.

Testing at Santé Labs

Lp(a) is not part of any profile you can book at Santé Labs today. The Standard Lipid Profile, which is coming soon, does not include it either.

If you want a view of your standard lipids now, you can book the Glycaemic Control Profile in Barcelona. It measures glucose, HbA1c, total cholesterol, HDL, LDL, triglycerides, creatinine and estimated glomerular filtration rate (eGFR). It does not include Lp(a). We measure and explain your results. Please discuss them with your doctor.

FAQ

Do I really only need to test Lp(a) once?

For most adults, yes. The EAS says repeat measurement is not required because it does not improve risk prediction [1]. Kidney disease, liver disease, acute infection and some life stages are exceptions [1][4]. Ask your doctor if any apply to you.

Can I convert my mg/dL result to nmol/L?

Not reliably. The EAS advises against a standard conversion factor and calls 2 to 2.5 only a best guess [1]. If you need a result in a specific unit, ask for a test that reports it directly.

Can diet or exercise lower my Lp(a)?

Only slightly. The EAS describes the effect of lifestyle as minimal, with a possible 10% to 15% drop on a low carbohydrate, high fat diet [1]. Lifestyle still matters for your other risk factors.

Should my family get tested?

The EAS and SEA support testing close relatives of people with high Lp(a) [1][4]. Discuss it with your doctor.

References

  1. Kronenberg F, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 – https://pmc.ncbi.nlm.nih.gov/articles/PMC9639807/
  2. Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020 – https://academic.oup.com/eurheartj/article/41/1/111/5556353
  3. Mach F, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025 – https://doi.org/10.1093/eurheartj/ehaf190
  4. Delgado-Lista J, et al. Consensus on lipoprotein(a) of the Spanish Society of Arteriosclerosis. Clin Investig Arterioscler. 2024 – https://www.elsevier.es/en-revista-clinica-e-investigacion-arteriosclerosis-english-415-articulo-consensus-on-lipoprotein-a-spanish-society-S2529912324000524
Compartir

Plan Superhuman

Mide tu ApoB.Y más de 100 biomarcadores en total.

Una analítica completa al año en el laboratorio y un plan de acción claro.

495 € al año, con renovación anual. Cancela la renovación desde la app. Si tu médico no aprueba la solicitud, te devolvemos todo lo pagado. La lista exacta depende de tu sexo y tu edad.

Sigue leyendo

Artículos relacionados.Para leer junto a este.

Ver el blog
Ver el blog